Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

CareDx, Inc.

NASDAQ: CDNA · Industrial Applications and Services · 7 alerts · CIK 1217234

Share price
$73.72Close, Nov 16
Market cap
$3.87B
Shares outstanding
52.54MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CareDx, Inc. filings on SEC EDGAR ↗

4:35 PM ET Form 4
Insider Selling

CareDx Director Michael Goldberg Sells $1.09M of Stock

Michael Goldberg, Director, sold 13,800 shares of CareDx, Inc. at $78.32 to $79.85 a share (average $79.15) in 3 transactions, worth $1.09M in total on Nov 12, 2026. Shares held after the trade: 48,526 (-4.4%).

Value
$1.09M
Shares
13,800
Average price
$79.15
Role
Director
Holding change
-4.4%
Trade date
Nov 12, 2026
4:33 PM ET Form 4
Insider Selling

CareDx CFO & COO Keith Kennedy Sells $166K of Stock

Keith Kennedy, CFO & COO, sold 2,097 shares of CareDx, Inc. at $78.78 to $79.61 a share (average $79.29) in 2 transactions, worth $166K in total on Nov 12, 2026. Shares held after the trade: 199,147 (-0.6%).

Value
$166K
Shares
2,097
Average price
$79.29
Role
CFO & COO
Holding change
-0.6%
Trade date
Nov 12, 2026
4:29 PM ET Form 4
Insider Selling

CareDx Secretary and General Counsel Jeffrey Adam Novack Sells $332K of Stock

Jeffrey Adam Novack, Secretary and General Counsel, sold 4,096 shares of CareDx, Inc. at $80.47 to $83.33 a share (average $81.13) in 3 transactions, worth $332K in total on Nov 10, 2026. Shares held after the trade: 96,604 (-0.9%).

Value
$332K
Shares
4,096
Average price
$81.13
Role
Secretary and General Counsel
Holding change
-0.9%
Trade date
Nov 10, 2026
6:26 PM ET Form 4
Insider Selling

CareDx CFO & COO Keith Kennedy Sells $4.82M of Stock

Keith Kennedy, CFO & COO, sold 61,961 shares of CareDx, Inc. at $76.55 to $83.60 a share (average $77.82) in 8 transactions, worth $4.82M in total on Nov 5, 2026. Shares held after the trade: 199,147 (-0.3%).

Value
$4.82M
Shares
61,961
Average price
$77.82
Role
CFO & COO
Holding change
-0.3%
Trade date
Nov 5, 2026
4:05 PM ET 10-Q
Financial Results

CareDx Q3 2026 Results: Net Income $19.3M, Up 1051.8% YoY

CareDx reported a significant increase in total revenue to $389.0 million for the nine months ended September 30, 2026, compared to $271.4 million in the prior year. The company achieved a net income of $132.7 million during this period, primarily driven by a $113.0 million gain from the sale of its lab products business and strong growth in testing services revenue.

Key figure
Net income $19.3M · +1051.8% YoY
4:03 PM ET 8-K
Financial Results

CareDx Financial Results

CareDx reported third quarter 2026 revenue of $139 million, a 39% year-over-year increase driven by strong growth in Testing Services. The company achieved GAAP net income of $19 million and raised its full-year 2026 revenue guidance to a range of $520 million to $530 million.

“We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy.”

John Hanna, President and Chief Executive Officer of CareDx

“We see significant clinical interest in how molecular information can inform more decisions across a patient’s care journey, while continuing to make our solutions easier for providers to adopt and patients to access. We believe these dynamics create meaningful opportunities for continued profitable growth.”

John Hanna, President and Chief Executive Officer of CareDx
4:07 PM ET 8-K/A
M&A Deal

CareDx M&A Deal with Naveris, Inc.

CareDx, Inc. filed an amendment to its original 8-K to provide required historical financial statements and pro forma financial information regarding its completed acquisition of Naveris, Inc. The acquisition was originally reported as completed on July 7, 2026. The filing includes audited financial statements for Naveris for the year 2025 and unaudited figures for the first quarter of 2026.

Counterparty
Naveris, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.